Ladenburg Thalmann Financial Services Inc. Acquires 2,980 Shares of Inogen Inc (NASDAQ:INGN)

Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Inogen Inc (NASDAQ:INGN) by 235.9% during the 2nd quarter, Holdings Channel reports. The firm owned 4,243 shares of the medical technology company’s stock after purchasing an additional 2,980 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Inogen were worth $283,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Advisor Group Inc. increased its holdings in shares of Inogen by 71.4% during the second quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 192 shares during the period. Arizona State Retirement System lifted its holdings in shares of Inogen by 1.6% during the second quarter. Arizona State Retirement System now owns 13,051 shares of the medical technology company’s stock worth $871,000 after purchasing an additional 206 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of Inogen by 3.5% during the second quarter. Oregon Public Employees Retirement Fund now owns 7,273 shares of the medical technology company’s stock worth $486,000 after purchasing an additional 244 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in shares of Inogen by 4.1% during the second quarter. State Board of Administration of Florida Retirement System now owns 9,933 shares of the medical technology company’s stock worth $663,000 after purchasing an additional 390 shares during the period. Finally, Polen Capital Management LLC lifted its holdings in shares of Inogen by 8.6% during the second quarter. Polen Capital Management LLC now owns 5,083 shares of the medical technology company’s stock worth $339,000 after purchasing an additional 404 shares during the period.

In related news, Director Loren L. Mcfarland purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average cost of $42.93 per share, with a total value of $42,930.00. Following the completion of the purchase, the director now owns 4,481 shares in the company, valued at approximately $192,369.33. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Heath Lukatch purchased 2,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was bought at an average cost of $43.01 per share, with a total value of $86,020.00. Following the completion of the purchase, the director now owns 5,481 shares of the company’s stock, valued at approximately $235,737.81. The disclosure for this purchase can be found here. Insiders own 4.54% of the company’s stock.

INGN stock opened at $48.98 on Friday. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 4.09 and a beta of 1.51. The company has a quick ratio of 6.82, a current ratio of 7.35 and a debt-to-equity ratio of 0.01. Inogen Inc has a 12-month low of $41.19 and a 12-month high of $207.50. The company’s fifty day simple moving average is $47.24 and its 200 day simple moving average is $62.58.

Inogen (NASDAQ:INGN) last released its earnings results on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). The firm had revenue of $101.10 million during the quarter, compared to analyst estimates of $106.88 million. Inogen had a net margin of 11.24% and a return on equity of 13.34%. Inogen’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.65 EPS. Research analysts expect that Inogen Inc will post 1.09 earnings per share for the current year.

INGN has been the topic of a number of recent research reports. ValuEngine upgraded shares of Inogen from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. BidaskClub lowered shares of Inogen from a “sell” rating to a “strong sell” rating in a report on Friday, August 9th. Piper Jaffray Companies cut their price target on shares of Inogen from $140.00 to $80.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. KeyCorp reiterated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. Finally, Stifel Nicolaus lowered shares of Inogen from a “buy” rating to a “hold” rating and cut their price target for the stock from $85.00 to $48.00 in a report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $82.17.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.